Sun Pharmaceutical Industries quarterly results and financials

Sun Pharmaceutical Industries (SUNPHARMA)₹1,905−0.55%(9 Nov 2026 close)Pharmaceuticals

Key facts

In the Sep 2026 quarter (consolidated), Sun Pharmaceutical Industries reported sales of ₹16,142 Cr, up 11.8% from Sep 2025, and net profit of ₹1,997 Cr, down 36.1% year on year. For the year to Mar 2026, sales were ₹58,245 Cr and net profit ₹11,518 Cr.

Sales (Sep 2026): ₹16,142 Cr
Net profit (Sep 2026): ₹1,997 Cr
Sales (FY Mar 2026): ₹58,245 Cr
Net profit (FY Mar 2026): ₹11,518 Cr
EPS (Sep 2026): ₹8.26
Borrowings (Mar 2026): ₹4,641 Cr

Company filings, consolidated accounts; latest reported quarter Sep 2026

Sun Pharmaceutical Industries quarterly results

₹ crore unless stated; each column is a quarter.

Sun Pharmaceutical Industries Quarterly results
	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Sales	12,332	11,946	12,613	13,243	13,615	12,909	13,804	14,433	15,464	14,558	15,239	16,142
Expenses	8,877	8,923	9,021	9,330	9,644	9,216	9,520	9,930	10,540	10,626	10,844	11,428
Operating Profit	3,464	3,027	3,594	3,926	3,994	3,703	4,290	4,515	4,935	3,942	4,406	4,727
OPM %	28.1%	25.1%	29.1%	30.1%	29.1%	29.1%	31.0%	31.0%	32.1%	27.1%	29.0%	29.1%
Other Income	180	503	532	354	149	251	−354	470	88.94	458	520	−751
Interest	34.97	73.93	61.99	68.99	51.98	48.94	74.92	99.93	77.96	86.02	100	74.96
Depreciation	622	650	656	627	631	665	701	730	732	776	740	759
Profit before tax	2,991	2,810	3,417	3,591	3,467	3,246	3,164	4,161	4,219	3,545	4,088	3,152
Tax %	13.9%	5.0%	15.9%	15.9%	16.0%	34.0%	27.0%	24.9%	19.9%	22.9%	28.9%	36.9%
Exceptional items	−60.13	−96.28	0.00	0.00	−265	−241	−595	0.00	−395	0.00	−145	−806
Net Profit	2,564	2,662	2,864	3,041	2,916	2,156	2,296	3,128	3,383	2,712	2,902	1,997
EPS (Rs)	10.49	11.03	11.79	12.64	12.06	8.93	9.47	12.96	14.00	11.28	12.02	8.26

Sun Pharmaceutical Industries profit and loss

₹ crore unless stated; years end in March. TTM is the last four quarters.

Sun Pharmaceutical Industries Profit and loss
	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	28,356	31,444	26,377	28,977	32,704	33,395	38,530	43,691	48,348	52,375	58,245	61,404
Expenses	20,268	21,425	20,790	22,625	25,784	24,953	28,310	32,123	35,381	37,356	41,833	43,438
Operating Profit	8,147	10,064	5,615	6,357	6,958	8,438	10,219	11,602	12,982	15,063	16,452	18,009
OPM %	29.1%	32.0%	21.0%	22.0%	21.1%	25.1%	27.1%	27.1%	27.1%	29.1%	28.1%	29.3%
Other Income	−41.94	609	−135	−258	382	−3,445	−3,501	459	864	1,444	1,894	315
Interest	523	400	518	554	303	141	127	172	238	231	339	339
Depreciation	1,039	1,266	1,501	1,754	2,054	2,084	2,146	2,530	2,559	2,579	2,941	3,006
Profit before tax	6,562	9,025	3,472	3,801	4,999	2,793	4,475	9,389	11,065	13,718	15,092	15,004
Tax %	13.9%	12.9%	25.9%	16.0%	15.9%	17.9%	23.9%	9.0%	13.0%	20.0%	23.9%	—
Exceptional items	−483	32.06	−701	−999	−196	−2,829	−3,452	−131	−415	−528	−951	−1,346
Net Profit	5,660	7,853	2,542	3,213	4,173	2,274	3,390	8,523	9,620	10,974	11,518	10,994
EPS (Rs)	18.82	28.95	8.71	11.08	15.64	12.07	13.59	35.18	39.80	45.38	47.71	45.56
Dividend payout %	5.0%	12.0%	23.0%	25.0%	25.0%	62.0%	73.0%	33.0%	34.0%	35.0%	33.0%	—

Sun Pharmaceutical Industries balance sheet

₹ crore, at each year end.

Sun Pharmaceutical Industries Balance sheet
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	207	242	241	240	240	241	241	240	241	241	240	240
Reserves	25,431	32,772	36,455	38,100	41,162	45,041	46,228	47,793	55,762	63,498	72,020	83,312
Borrowings	9,024	8,524	9,865	10,423	10,549	8,344	3,880	1,294	6,911	3,287	2,370	4,641
Other Liabilities	14,157	14,015	14,694	15,673	12,727	14,685	17,374	20,572	17,917	18,475	17,411	20,307
Total Liabilities	48,819	55,553	61,254	64,436	64,680	68,310	67,721	69,901	80,830	85,500	92,042	1,08,500
Fixed Assets	12,717	15,909	17,730	18,900	21,880	22,909	21,598	22,719	24,147	23,324	22,636	32,885
CWIP	2,040	2,177	2,802	2,467	1,411	1,220	1,567	1,288	4,974	5,355	6,650	3,052
Investments	2,707	1,825	1,188	7,114	7,876	10,112	9,586	12,797	14,763	14,974	18,288	24,630
Other Assets	31,355	35,642	39,534	35,956	33,513	34,069	34,970	33,097	36,945	41,847	44,468	47,933
Inventories	5,669	6,423	6,829	6,886	7,885	7,872	8,991	8,919	10,513	9,864	10,248	11,493
Trade receivables	5,111	6,787	7,212	7,827	8,889	9,430	9,075	10,492	11,446	11,263	13,055	15,524
Cash & equivalents	11,005	13,174	15,144	9,934	7,281	6,485	6,444	5,031	5,771	10,525	11,327	11,604
Total Assets	48,819	55,553	61,254	64,436	64,680	68,310	67,721	69,901	80,830	85,500	92,042	1,08,500

Sun Pharmaceutical Industries cash flow

₹ crore, for each year.

Sun Pharmaceutical Industries Cash flow
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from operating activity	5,618	6,685	7,083	3,906	2,198	6,560	6,174	8,995	4,959	12,136	14,076	12,420
Cash from investing activity	−1,501	−3,951	−4,189	−3,105	−310	−2,227	407	−5,553	−7,217	−763	−5,181	−10,408
Cash from financing activity	−1,185	−1,883	−2,280	−1,535	−2,722	−5,696	−5,969	−5,181	2,369	−6,692	−7,882	−2,505
Net cash flow	2,921	846	609	−734	−843	−1,383	595	−1,762	115	4,650	981	−497
Capex	2,353	3,407	3,694	1,962	3,216	1,542	1,171	1,497	2,088	2,205	2,130	3,610
Free cash flow	3,311	3,343	3,485	2,009	−964	5,096	5,084	7,530	2,887	9,946	11,987	8,883
CFO / OP %	93.0%	106.0%	90.0%	83.0%	48.0%	113.0%	85.0%	78.0%	56.0%	105.0%	96.0%	89.0%

Sun Pharmaceutical Industries ratios

Working-capital days and returns, by year.

Sun Pharmaceutical Industries Ratios
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor days	67	86	82	107	111	104	98	98	94	84	90	96
Inventory days	306	369	306	337	365	310	377	314	359	337	347	362
Days payable	178	207	197	234	192	142	167	158	194	194	210	232
Cash conversion cycle	198	252	194	213	286	275	311	256	262	230	229	229
Working capital days	−8	36	−5	−32	30	50	50	46	39	54	64	53
ROCE %	23.1%	18.1%	20.1%	10.1%	10.1%	10.1%	13.1%	17.1%	16.1%	17.1%	20.1%	21.1%

Sun Pharmaceutical Industries: frequently asked questions

What are the latest quarterly results of Sun Pharmaceutical Industries?

For the Sep 2026 quarter, Sun Pharmaceutical Industries reported sales of ₹16,142 Cr, up 11.8% year on year and net profit of ₹1,997 Cr, down 36.1% year on year. The operating margin was 29.1%.

What is the annual revenue of Sun Pharmaceutical Industries?

Sun Pharmaceutical Industries' sales for the year to Mar 2026 were ₹58,245 Cr; over the last twelve months they were ₹61,404 Cr.

What is the net profit of Sun Pharmaceutical Industries?

Net profit for the year to Mar 2026 was ₹11,518 Cr, and ₹10,994 Cr over the last twelve months. Earnings per share over the same trailing period were ₹45.56.

How much debt does Sun Pharmaceutical Industries have?

Sun Pharmaceutical Industries reported borrowings of ₹4,641 Cr at Mar 2026, against cash and equivalents of ₹11,604 Cr.

What is the free cash flow of Sun Pharmaceutical Industries?

Cash from operations was ₹12,420 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹8,883 Cr.

Loading…